Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SelK2 in Total Knee Arthroplasty
NCT03812328Phase 2Completed
- Sponsor
- Tetherex Pharmaceuticals
- Start
- Feb 2019
- Primary completion
- Oct 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of SelK2 in venous thromboembolism (VTE) (3 arms), sponsored by Tetherex Pharmaceuticals. Primary endpoints: Percentage of Participants With Total Venous Thromboembolism at 10 days and Percentage of Participants With Major or Clinically Relevant Non-major Bleeding Events at 10 days. Started Feb 2019; status: completed.
02
Drugs
SelK2
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03812328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812328.